BACKGROUND: The adult burden of atopic dermatitis (AD) is poorly characterized. OBJECTIVE: We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. METHODS: Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. RESULTS: Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. LIMITATIONS: This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. CONCLUSIONS:Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.
RCT Entities:
BACKGROUND: The adult burden of atopic dermatitis (AD) is poorly characterized. OBJECTIVE: We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. METHODS:Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. RESULTS: Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. LIMITATIONS: This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. CONCLUSIONS: Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.
Authors: Jonathan I Silverberg; Paras P Vakharia; Rishi Chopra; Ryan Sacotte; Neha Patel; Supriya Immaneni; Takeisha White; Robert Kantor; Derek Y Hsu Journal: J Allergy Clin Immunol Pract Date: 2017-11-10
Authors: Eric L Simpson; Emma Guttman-Yassky; David J Margolis; Steven R Feldman; Abrar Qureshi; Tissa Hata; Vera Mastey; Wenhui Wei; Laurent Eckert; Jingdong Chao; Renée J G Arnold; Tiffany Yu; Francis Vekeman; Mayte Suárez-Fariñas; Abhijit Gadkari Journal: JAMA Dermatol Date: 2018-08-01 Impact factor: 10.282
Authors: Quinn Thibodeaux; Mary Patricia Smith; Karen Ly; Kristen Beck; Wilson Liao; Tina Bhutani Journal: Hum Vaccin Immunother Date: 2019-03-27 Impact factor: 3.452
Authors: Mohamed A Kamal; John D Davis; Pavel Kovalenko; Kamal Srinivasan; Eric L Simpson; Takeshi Nakahara; Makoto Sugaya; Atsuyuki Igarashi; Marius Ardeleanu; Christine Xu; Kazuhiko Arima Journal: Clin Transl Sci Date: 2022-08-20 Impact factor: 4.438
Authors: K R Patel; V Singam; P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; R Kantor; D Y Hsu; J I Silverberg Journal: Br J Dermatol Date: 2018-11-12 Impact factor: 9.302